



### Bernard and Francine Dorval / William E. Rawls Prizes (early career awards):

Nominees will be evaluated according to the criteria described below.

Overall contributions to cancer research and potential to lead to (or evidence of having led to) improved cancer prevention, diagnosis, treatments, care, support, or cancer control will be considered. Circumstances which may have impacted the nominee's academic career progression and research productivity are taken into consideration, including but not limited to:

- Additional training requirements and career interruptions (personal (including 'two-body' problem<sup>1</sup> in academia), family responsibilities, medical leaves etc.) contributing to a non-linear or unconventional career trajectory
- Inequitable distribution of institutional resources including start-up packages, laboratory or office space and formal mentorship
- Historical policies and procedures that perpetuate biases in hiring, tenure and promotion
- Biases in assignment of authorship roles in publications (e.g. first and last author roles)
- Underrepresentation of individuals from the four designated groups (women, Indigenous peoples, persons with disabilities and members of visible minorities) among conference keynote speakers and/or panelists and invited lecturers

Expectations for excellence will be commensurate with the research discipline and relative career stage of the nominee.

#### Criteria:

- **Research productivity:** nominee's publication record in peer-reviewed journals, quality and type of scholarly work published, degree of contribution, number of citations, and continuity of publication production (barring any interruptions); other forms of research outputs including, but not limited to, conference proceedings, policy reports, patents, and commercialization products.
- **Research grant funding:** as the lead investigator and as part of multi-investigator teams (noting that multi-investigator teams may require additional time/effort to generate successful outcomes); nominee's role(s) and potential impact of contribution(s) to the team will be considered.
- **Fellowships, honours, and/or awards received by the nominee:** scope and relevance (i.e. provincial, national, or international) of distinctions received will be considered.
- **Training the next generation of cancer researchers:** relative to career stage and other considerations (career interruptions, for example), evidence of participation in a meaningful way and to an appropriate degree towards the mentorship and support of trainees and fellows; evidence that trainees and fellows have been subsequently recognized for excellence themselves.
- **Contributions made to date to scientific discipline:** details of these and how critical they are/have been for advancing the knowledge in their immediate research field and the general scientific body of cancer research; potential for future contributions based on track record will be considered.
- **Evidence (potential) of (for) leadership on a national and international scale:** senior author publications in high quality journals (and citations thereof); success in securing peer-reviewed research funding as a lead investigator; invitations to present at national and international conferences; participation on peer review panels and other professional contributions; community outreach; forging national and international collaborations; and importantly, impact (or likelihood of impact) on cancer prevention, diagnosis, treatment, care and/or support in the Canadian population and internationally.

---

<sup>1</sup> Refers to dual-academic couples facing the challenge of both individuals obtaining desirable positions within a reasonable commuting distance.



Score Range & Descriptor	Nominee Rating Scale Bernard and Francine Dorval / William E. Rawls Prizes (early career awards)
4.7-5.0 Exceptional	<ul style="list-style-type: none"> <li>• Candidate is extremely likely to become (or has already become) a leader in cancer research in Canada and internationally</li> <li>• Exceptional contributions made to date to their scientific discipline and potential impact of future contributions based on track record</li> <li>• Exceptional research productivity and track record in obtaining research grant funding relative to career stage</li> <li>• Exceptional track record in mentorship and/or potential to attract high quality personnel</li> <li>• Exceptional track record in obtaining fellowships, honours and/or awards</li> </ul>
4.3-4.6 Excellent	<ul style="list-style-type: none"> <li>• Candidate is likely to become (or has already become) a leader in cancer research in Canada and internationally</li> <li>• Excellent contributions made to date to their scientific discipline and potential impact of future contributions based on track record</li> <li>• Excellent research productivity and track record in obtaining research grant funding relative to career stage</li> <li>• Excellent track record in mentorship and/or potential to attract high quality personnel</li> <li>• Excellent track record in obtaining fellowships, honours and/or awards</li> </ul>
3.9-4.2 Very good	<ul style="list-style-type: none"> <li>• Very good candidate who has the potential to become a leader in cancer research in Canada and internationally</li> <li>• Very good contributions made to date to their scientific discipline and potential impact of future contributions based on track record</li> <li>• Very good research productivity and track record in obtaining research grant funding relative to career stage</li> <li>• Very good track record in mentorship and/or potential to attract high quality personnel</li> <li>• Very good track record in obtaining fellowships, honours and/or awards</li> </ul>
3.5-3.8 Good	<ul style="list-style-type: none"> <li>• Good candidate who has some potential to become a leader in cancer research in Canada and internationally</li> <li>• Good contributions made to date to their scientific discipline and potential impact of future contributions based on track record</li> <li>• Good research productivity and track record in obtaining research grant funding relative to career stage</li> <li>• Good track record in mentorship and/or potential to attract high quality personnel</li> <li>• Good track record in obtaining fellowships, honours and/or awards</li> </ul>
3.0-3.4* Fair	<ul style="list-style-type: none"> <li>• Fair candidate who has limited potential to become a leader in cancer research in Canada</li> <li>• Fair contributions made to date to their scientific discipline and limited potential impact of future contributions based on track record</li> <li>• Fair research productivity and track record in obtaining research grant funding relative to career stage</li> <li>• Fair track record in mentorship and/or potential to attract high quality personnel</li> <li>• Fair track record in obtaining fellowships, honours and/or awards</li> </ul>
Below 3.0 Poor	<ul style="list-style-type: none"> <li>• Poor candidate who has low potential to become a leader in cancer research in Canada</li> <li>• Poor contributions made to date to their scientific discipline and low potential to yield impactful contributions in the future based on track record</li> <li>• Poor research productivity and track record in obtaining research grant funding relative to career stage</li> <li>• Poor track record in mentorship and/or potential to attract high quality personnel</li> <li>• Poor track record in obtaining fellowships, honours and/or awards</li> </ul>

\*Nominees scoring below 3.5 as an average of final scores will not be considered eligible to receive a prize.



### Robert L. Noble / O. Harold Warwick Prizes (established career awards):

Nominees will be evaluated according to the criteria described below.

Overall contributions to cancer research and the significance of their accomplishments to cancer prevention, diagnosis, treatment, care, support or cancer control in Canada and internationally will be considered.

Circumstances which may have impacted the nominee's academic career progression and research productivity are taken into consideration, including but not limited to:

- Additional training requirements and career interruptions (personal (including 'two-body' problem<sup>2</sup> in academia), family responsibilities, medical leaves, etc.) contributing to a non-linear or unconventional career trajectory
- Inequitable distribution of institutional resources including start-up packages, laboratory or office space and formal mentorship
- Historical policies and procedures that perpetuate biases in hiring, tenure and promotion
- Biases in assignment of authorship roles in publications (e.g. first and last author roles)
- Underrepresentation of individuals from the four designated groups (women, Indigenous peoples, persons with disabilities and members of visible minorities) among conference keynote speakers and/or panelists and invited lecturers

#### Criteria:

- **Research productivity and outputs:** nominee's publication record in peer-reviewed journals, quality and type of scholarly work published, degree of contribution, number of citations, and continuity of publication production (barring any interruptions); other forms of research outputs including, but not limited to, conference proceedings, policy reports, patents, and commercialization products.
- **Research grant funding:** as the lead investigator and as part of multi-investigator teams (noting that multi-investigator teams may require additional time/effort to generate successful outcomes); nominee's role(s) and potential impact of contribution(s) to the team will be considered.
- **Honours, and/or awards received by the nominee:** scope and relevance (i.e. provincial, national, or international) of distinctions received will be considered.
- **Training the next generation of cancer researchers:** relative to career stage and other considerations (career interruptions, for example), evidence of participation in a meaningful way and to an appropriate degree towards the mentorship and support of trainees and fellows; evidence that trainees and fellows have been subsequently recognized for excellence themselves and/or gone on to realize cancer research impacts themselves
- **Contributions/discoveries made to cancer research:** details of these and how critical they have been for advancing knowledge both in their immediate research field and for the general scientific body of cancer research; the importance of resulting impacts on cancer prevention, diagnosis, treatment, care, support or cancer control in Canada and internationally will be considered.
- **Evidence of leadership on a national and international scale:** recognition as an expert by peers, senior author publications in high quality journals, success in securing peer-reviewed research funding as a lead investigator, invitations to present at national and international conferences, participation on peer review panels, editorial boards and other professional contributions, community outreach, national and international collaborations will be considered; and importantly, demonstrated impact on cancer prevention, diagnosis, treatment, care and/or support in the Canadian population and internationally.

---

<sup>2</sup> Refers to dual-academic couples facing the challenge of both individuals obtaining desirable positions within a reasonable commuting distance.



Score Range & Descriptor	Nominee Rating Scale <b>Robert L. Noble / O. Harold Warwick Prizes (established career awards)</b>
4.7-5.0 Exceptional	<ul style="list-style-type: none"> <li>• Exceptional evidence of scientific leadership on a national and international scale</li> <li>• Exceptional contributions/discoveries made to date in their scientific discipline</li> <li>• Exceptional research productivity and track record in obtaining research grant funding</li> <li>• Exceptional and relevant recognition through honours and awards</li> <li>• Exceptional track record in mentorship/training of the next generation of cancer researchers</li> <li>• Exceptional impact on cancer prevention, diagnosis, treatment, care and/or support in the Canadian population and internationally</li> </ul>
4.3-4.6 Excellent	<ul style="list-style-type: none"> <li>• Excellent evidence of scientific leadership on a national and international scale</li> <li>• Excellent contributions/discoveries made to date in their scientific discipline</li> <li>• Excellent research productivity and track record in obtaining research grant funding</li> <li>• Excellent and relevant recognition through honours and awards</li> <li>• Excellent track record in mentorship/training of the next generation of cancer researchers</li> <li>• Excellent impact on cancer prevention, diagnosis, treatment, care and/or support in the Canadian population and internationally</li> </ul>
3.9-4.2 Very good	<ul style="list-style-type: none"> <li>• Very good evidence of scientific leadership on a national and/or international scale</li> <li>• Very good contributions/discoveries made to date in their scientific discipline</li> <li>• Very good research productivity and track record in obtaining research grant funding</li> <li>• Very good recognition through honours and awards</li> <li>• Very good track record in mentorship/training of the next generation of cancer researchers</li> <li>• Very good impact on cancer prevention, diagnosis, treatment, care and/or support in the Canadian population and/or internationally</li> </ul>
3.5-3.8 Good	<ul style="list-style-type: none"> <li>• Good evidence of some scientific leadership in Canada</li> <li>• Good contributions/discoveries made to date in their scientific discipline</li> <li>• Good research productivity and track record in obtaining research grant funding</li> <li>• Good recognition through honours and awards</li> <li>• Good track record in mentorship/training of the next generation of cancer researchers</li> <li>• Good impact on cancer prevention, diagnosis, treatment, care and/or support in the Canadian population and/or internationally</li> </ul>
3.0-3.4* Fair	<ul style="list-style-type: none"> <li>• Limited evidence of scientific leadership in Canada</li> <li>• Fair contributions made to date to their scientific discipline</li> <li>• Fair research productivity and track record in obtaining research grant funding</li> <li>• Fair recognition through honours and awards</li> <li>• Fair track record in mentorship/training of the next generation of cancer researchers</li> <li>• Limited impact on cancer prevention, diagnosis, treatment, care and/or support in the Canadian population or internationally</li> </ul>
Below 3.0 Poor	<ul style="list-style-type: none"> <li>• Poor/no evidence of scientific leadership in Canada</li> <li>• Poor contributions made to date in their scientific discipline</li> <li>• Poor research productivity and track record in obtaining research grant funding</li> <li>• Poor recognition through honours and awards</li> <li>• Poor track record in mentorship/training of the next generation of cancer researchers</li> <li>• Limited to no impact on cancer prevention, diagnosis, treatment, care and/or support in the Canadian population or internationally</li> </ul>

\*Nominees scoring below 3.5 as an average of final scores will not be considered eligible to receive a prize.



### Canadian Cancer Society Lifetime Contribution Prize (established career award):

Nominees will be evaluated according to the criteria described below.

Primary consideration will be given to the nominee's contributions to cancer research that extend beyond traditional research accomplishments and outputs to have a significant impact on the Canadian cancer research ecosystem. A demonstrated commitment to training the next generation of cancer researchers must be evident. Circumstances which may have impacted the nominee's academic career progression and research productivity are taken into consideration, including but not limited to:

- Additional training requirements and career interruptions (personal (including 'two-body' problem<sup>3</sup> in academia), family responsibilities, medical leaves, etc.) contributing to a non-linear or unconventional career trajectory
- Inequitable distribution of institutional resources including start-up packages, laboratory or office space and formal mentorship
- Historical policies and procedures that perpetuate biases in hiring, tenure and promotion
- Biases in assignment of authorship roles in publications (e.g. first and last author roles)
- Underrepresentation of individuals from the four designated groups (women, Indigenous peoples, persons with disabilities and members of visible minorities) among conference keynote speakers and/or panelists and invited lecturers

#### Criteria:

- Contributions to the Canadian cancer research ecosystem, and internationally, as applicable: vision and leadership in building networks, fostering collaborations, developing resources and infrastructure, and other contribution(s) that have/has significantly enhanced the cancer research ecosystem in Canada and internationally. The degree to which these contributions have impacted those affected by cancer, in Canada and internationally, as applicable, will be considered.
- Training the next generation of researchers: relative to career stage and other considerations (career interruptions, for example), evidence that the nominee participates in a meaningful way and to an appropriate degree towards the mentorship and support of trainees and fellows; evidence that trainees and fellows have been subsequently recognized for excellence themselves, including but not limited to securing academic positions in cancer research.
- Other considerations (to a lesser degree) include:
  - research productivity and outputs: publication record in peer-reviewed journals, quality and type of scholarly work published, degree of contribution, number of citations, and continuity of publication production (barring any interruptions); other forms of research outputs including, but not limited to, conference proceedings, policy reports, patents, and commercialization products
  - research grant funding: as the lead investigator and as part of multi-investigator teams (noting that multi-investigator teams may require additional time/effort to generate successful outcomes); the nominee's role(s) and potential impact of contribution(s) to the team.
  - honours, and/or awards: scope and relevance (i.e. provincial, national, or international) of distinctions received will be considered.
  - participation on peer review panels, editorial boards and other professional contributions, as well as community outreach and advocacy.

---

<sup>3</sup> Refers to dual-academic couples facing the challenge of both individuals obtaining desirable positions within a reasonable commuting distance.



Score Range & Descriptor	Nominee Rating Scale  Lifetime Contribution Prize (established career award)
4.7-5.0  Exceptional	<ul style="list-style-type: none"> <li>• Exceptional evidence of visionary leadership that has enhanced the cancer research ecosystem on a national and international level</li> <li>• Exceptional impact on cancer prevention, diagnosis, treatment, care and/or support in the Canadian population and internationally</li> <li>• Exceptional track record in mentorship/training of the next generation of cancer researchers</li> <li>• Excellent research productivity, including publications and other outputs, grant funding, and professional contributions</li> <li>• Excellent and relevant recognition through honours and awards</li> </ul>
4.3-4.6  Excellent	<ul style="list-style-type: none"> <li>• Excellent evidence of visionary leadership that has enhanced the cancer research ecosystem on a national and/or international level</li> <li>• Excellent impact on cancer prevention, diagnosis, treatment, care and/or support in the Canadian population and/or internationally</li> <li>• Excellent track record in mentorship/training of the next generation of cancer researchers</li> <li>• Very good research productivity, including publications and other outputs, grant funding, and professional contributions</li> <li>• Very good and relevant recognition through honours and awards</li> </ul>
3.9-4.2  Very good	<ul style="list-style-type: none"> <li>• Very good evidence of leadership that has contributed to the cancer research ecosystem on a national and/or international level</li> <li>• Very good impact on cancer prevention, diagnosis, treatment, care and/or support in the Canadian population and/or internationally</li> <li>• Very good track record in mentorship/training of the next generation of cancer researchers</li> <li>• Good research productivity, including publications and other outputs, grant funding, and professional contributions</li> <li>• Good and relevant recognition through honours and awards</li> </ul>
3.5-3.8  Good	<ul style="list-style-type: none"> <li>• Good evidence of leadership that has contributed to the cancer research ecosystem on a national and/or international level</li> <li>• Good impact on cancer prevention, diagnosis, treatment, care and/or support in the Canadian population and/or internationally</li> <li>• Good track record in mentorship/training of the next generation of cancer researchers</li> <li>• Fair research productivity, including publications and other outputs, grant funding, and professional contributions</li> <li>• Fair recognition through honours and awards</li> </ul>
3.0-3.4*  Fair	<ul style="list-style-type: none"> <li>• Fair evidence of leadership that has contributed to the cancer research ecosystem on a national and/or international level</li> <li>• Fair impact on cancer prevention, diagnosis, treatment, care and/or support in the Canadian population and/or internationally</li> <li>• Fair track record in mentorship/training of the next generation of cancer researchers</li> <li>• Minimal research productivity, including publications and other outputs, grant funding, and professional contributions</li> <li>• Minimal recognition through honours and awards</li> </ul>
Below 3.0  Poor	<ul style="list-style-type: none"> <li>• Limited to no evidence of leadership that has contributed to the cancer research ecosystem on a national and/or international level</li> <li>• Limited to no impact on cancer prevention, diagnosis, treatment, care and/or support in the Canadian population and/or internationally</li> <li>• Poor track record in mentorship/training of the next generation of cancer researchers</li> <li>• Limited to no research productivity, including publications and other outputs, grant funding, and professional contributions</li> <li>• Limited to no recognition through honours and awards</li> </ul>

\*Nominees scoring below 3.5 as an average of final scores will not be considered eligible to receive a prize.



**Canadian Cancer Society Inclusive Excellence Prize (any career stage award):**

Nominees will be evaluated according to the criteria described below.

Demonstrated leadership in the advancement of equity, diversity, inclusion, and accessibility leading to significant, measurable impacts that may include greater diversity in Canada's cancer research ecosystem, and/or enhanced equity in the delivery of cancer care for underserved populations will be considered.

Circumstances which may have impacted the nominee's career progression and research productivity (where applicable) are taken into consideration, including but not limited to:

- Additional training requirements and career interruptions (personal (including 'two-body' problem<sup>4</sup> in academia), family responsibilities, medical leaves, disruptions brought by the COVID-19 pandemic, etc.) contributing to a non-linear or unconventional career trajectory.
- Inequitable distribution of institutional resources including start-up packages, laboratory or office space and formal mentorship.
- Historical policies and procedures that perpetuate biases in hiring, tenure and promotion.
- Biases in assignment of authorship roles in publications (e.g. first and last author roles).
- Underrepresentation of individuals from the four designated groups (women, Indigenous peoples, persons with disabilities and members of visible minorities) among conference keynote speakers and/or panelists and invited lecturers.

Criteria:

- Demonstrated leadership and a genuine commitment to the advancement of equity, diversity, inclusion and accessibility as it relates to the Canadian cancer research ecosystem including but not limited to: administrative/committee work; development and implementation of programs/strategies/policies; advocacy; a specific program of research; and/or recruitment, training and mentorship activities.

**And/or:**

- Demonstrated leadership and a genuine commitment to the advancement of health equity and reduction of health disparities for underserved populations including but not limited to: history of working collaboratively with community partners to address health equity issues, development and implementation of programs/strategies/policies that promote equity-focused models of care.
- Evidence of impact may include: measurable (i.e. tangible) improvements in the diversity of Canada's cancer research landscape as a result of nominee's efforts in fostering inclusive excellence and/or enhanced equity in the delivery of cancer care for underserved populations.

---

<sup>4</sup> Refers to dual-academic couples facing the challenge of both individuals obtaining desirable positions within a reasonable commuting distance.





Score Range & Descriptor	Nominee Rating Scale <b>Inclusive Excellence Prize (any career stage award)</b>
4.7-5.0  Exceptional	<ul style="list-style-type: none"> <li>• Exceptional evidence of visionary leadership in the advancement of equity, diversity, inclusion and accessibility as it relates to the Canadian cancer research ecosystem.</li> <li>• Exceptional (measurably demonstrated) impact on the diversity of Canada’s cancer research landscape.</li> </ul> <b>And/or</b> <ul style="list-style-type: none"> <li>• Exceptional evidence of transformative leadership in the advancement of health equity across the cancer care continuum for underserved populations.</li> <li>• Strongly recognized as an equity, diversity, inclusion, and accessibility leader in Canada.</li> </ul>
4.3-4.6  Excellent	<ul style="list-style-type: none"> <li>• Excellent evidence of visionary leadership in the advancement of equity, diversity, inclusion and accessibility as it relates to the Canadian cancer research ecosystem.</li> <li>• Excellent (measurably demonstrated) impact on the diversity of Canada’s cancer research landscape.</li> </ul> <b>And/or</b> <ul style="list-style-type: none"> <li>• Excellent evidence of transformative leadership in the advancement of health equity across the cancer care continuum for underserved populations.</li> <li>• Recognized as an equity, diversity, inclusion and accessibility leader in Canada.</li> </ul>
3.9-4.2  Very good	<ul style="list-style-type: none"> <li>• Very good evidence of leadership in the advancement of equity, diversity inclusion, and accessibility as it relates to the Canadian cancer research ecosystem.</li> <li>• Very good (measurably demonstrated) impact on the diversity of Canada’s cancer research landscape.</li> </ul> <b>And/or</b> <ul style="list-style-type: none"> <li>• Very good evidence of transformative leadership in the advancement of health equity across the cancer care continuum for underserved populations.</li> <li>• Acknowledged as an equity, diversity, inclusion, and accessibility leader in Canada.</li> </ul>
3.5-3.8  Good	<ul style="list-style-type: none"> <li>• Good evidence of leadership in the advancement of equity, diversity, inclusion and accessibility as it relates to the Canadian cancer research ecosystem.</li> <li>• Good (measurably demonstrated) impact on the diversity of Canada’s cancer research landscape.</li> </ul> <b>And/or</b> <ul style="list-style-type: none"> <li>• Good evidence of transformative leadership in the advancement of health equity across the cancer care continuum for underserved populations.</li> <li>• Some recognition as an equity, diversity, inclusion, and accessibility leader in Canada.</li> </ul>
3.0-3.4*  Fair	<ul style="list-style-type: none"> <li>• Fair evidence of leadership in the advancement of equity, diversity, inclusion and accessibility as it relates to the Canadian cancer research ecosystem.</li> <li>• Fair (measurably demonstrated) impact on the diversity of Canada’s cancer research landscape.</li> </ul> <b>And/or</b> <ul style="list-style-type: none"> <li>• Fair evidence of transformative leadership in the advancement of health equity across the cancer care continuum for underserved populations.</li> <li>• Limited recognition as an equity, diversity, inclusion, and accessibility leader in Canada.</li> </ul>
Below 3.0  Poor	<ul style="list-style-type: none"> <li>• Limited to no evidence of leadership in the advancement of equity, diversity, inclusion, and accessibility as it relates to the Canadian cancer research ecosystem.</li> <li>• Limited to no (measurably demonstrated) impact on the diversity of Canada’s cancer research landscape.</li> </ul> <b>And/or</b> <ul style="list-style-type: none"> <li>• Limited to no evidence of leadership in the advancement of health equity across the cancer care continuum for underserved populations.</li> <li>• Limited to no recognition as an equity, diversity, inclusion and accessibility leader in Canada.</li> </ul>

\*Nominees scoring below 3.5 as an average of final scores will not be considered eligible to receive a prize.